Read by QxMD icon Read

Annals of Hematology

Kenichiro Hattori, Noriko Doki, Shuhei Kurosawa, Yutaro Hino, Keita Yamamoto, Masahiro Sakaguchi, Kaito Harada, Shuntaro Ikegawa, Naoki Shingai, Yasushi Senoo, Aiko Igarashi, Yuho Najima, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi
No abstract text is available yet for this article.
October 21, 2016: Annals of Hematology
Makoto Hirosawa, Takehiro Higashi, Atsushi Iwashige, Takahiro Yamaguchi, Junichi Tsukada
No abstract text is available yet for this article.
October 21, 2016: Annals of Hematology
Silvia Mangiacavalli, A Pompa, V Ferretti, C Klersy, F Cocito, M Varettoni, C S Cartia, M Cazzola, A Corso
Extramedullary relapse (EMR) represents a poor prognostic marker in the course of multiple myeloma (MM). We reviewed data from 329 patients, diagnosed between 2000 and 2010, without extramedullary disease at onset to explore possible risk factors for EMR. The median overall survival of our study cohort was 6.4 years. The risk of EMR was 28 % with a median time from diagnosis to first EMR of 2.2 years (0.2-9.1 years). Patients with soft tissue masses located in extra-osseous organs (EMR-S) showed the worst outcome, compared to those with tumor masses arising from adjacent bone (EMR-B) (median OS 1...
October 21, 2016: Annals of Hematology
Jean-Christophe Ianotto, Aurélie Chauveau, Dominique Mottier, Valérie Ugo, Christian Berthou, Eric Lippert, Aurélien Delluc
Cancer incidence in patients with recurrent unprovoked venous thromboembolism (VTE) is much higher than after a first event, but the incidence of myeloproliferative neoplasms (MPN) in this situation is still unknown. We tested for JAK2V617F and calreticulin mutants, 372 DNA samples of patients treated for (VTR). Among these patients, 10 (2.7%) were carrying JAK2V617F mutation and none of them any of the calreticulin (CALR) mutations. Among the 19 patients who had VTE recurrence under vitamin K antagonists, 4 patients (21...
October 20, 2016: Annals of Hematology
Khaoula Ben Younes, Raoudha Doghri, Karima Mrad, Neila Ben Romdhane, Fatma Ben Aissa-Fennira
No abstract text is available yet for this article.
October 20, 2016: Annals of Hematology
Hiroyuki Yamazaki, Kazunari Aoki, Tadakazu Kondo, Momoko Nishikori, Toshiyuki Kitano, Masakatsu Hishizawa, Kouhei Yamashita, Akifumi Takaori-Kondo
No abstract text is available yet for this article.
October 20, 2016: Annals of Hematology
Heiblig Maël, Bidet Audrey, Callet-Bauchu Evelyne, Dumas Pierre-Yves, Chabane Kaddour, Salles Gilles, Pigneux Arnaud
No abstract text is available yet for this article.
October 20, 2016: Annals of Hematology
Chiara Briani, Andrea Visentin, Tiziana Cavallaro, Mario Cacciavillani, Ilaria Cabrini, Sergio Ferrari, Renato Zambello, Livio Trentin
No abstract text is available yet for this article.
October 19, 2016: Annals of Hematology
Burak Uz
No abstract text is available yet for this article.
October 18, 2016: Annals of Hematology
Luiz Claudio Santos Thuler, Maria S Pombo-de-Oliveira
The WHO classification that defines subtypes of acute myeloid leukaemias (AMLs) is relatively unexplored at the population-based level. This study aimed to examine the frequency of acute promyelocytic leukaemia (APL or AML-M3) in Brazil. Data were extracted from 239 cancer centres (2001-2012) and categorized according to the International Classification of Diseases for Oncology (CID-O 3.0) and WHO classification (n = 9116). CID-O3 code 9866 identified 614 APL patients. AML not otherwise specified (NOS) was frequent, and the APL group represented the main subtype specified...
October 18, 2016: Annals of Hematology
C Martínez, A S Jorge, A Pereira, M Moreno, J Núñez, J Gayoso, J Gonzalez-Medina, N Revilla, A Sampol, E Domingo-Domenech, F de la Cruz, A Morales, M J Rodriguez-Salazar, S Valiente, E Pérez-Ceballos, J Pérez de Oteyza, R García-Sanz
Autologous hematopoietic cell transplantation (AHCT) is the standard of care for young patients with relapsed/refractory (R/R) Hodgkin's lymphoma (HL). However, there is limited experience of its efficacy and feasibility in older patients. The characteristics and outcomes of 121 patients aged ≥50 years (42 of them are ≥60 years old) with R/R HL who underwent AHCT were reviewed. After a median follow-up of 3.1 years, overall survival (OS) and progression-free survival (PFS) at 5 years were 64 and 55 %, respectively, with no differences between 50-59-year-old and ≥60-year-old patients...
October 18, 2016: Annals of Hematology
Kitsada Wudhikarn, Udomsak Bunworasate, Jakrawadee Julamanee, Arnuparp Lekhakula, Suporn Chuncharunee, Pimjai Niparuck, Supachai Ekwattanakit, Archrob Khuhapinant, Lalita Norasetthada, Weerasak Nawarawong, Nisa Makruasi, Nonglak Kanitsap, Chittima Sirijerachai, Kanchana Chansung, Peerapon Wong, Tontanai Numbenjapon, Kannadit Prayongratana, Tawatchai Suwanban, Somchai Wongkhantee, Pannee Praditsuktavorn, Tanin Intragumtornchai
Secondary central nervous system (CNS) relapse is a serious and fatal complication of diffuse large B cell lymphoma (DLBCL). Data on secondary CNS (SCNS) relapse were mostly obtained from western countries with limited data from developing countries. We analyzed the data of 2034 newly diagnosed DLBCL patients enrolled into the multi-center registry under Thai Lymphoma Study Group from setting. The incidence, September 2006 to December 2013 to represent outcome from a resource limited pattern, management, and outcome of SCNS relapse were described...
October 18, 2016: Annals of Hematology
Maria-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, Ana-Isabel Teruel, Enrique Bengoechea, Luis Palomera, Felipe de Arriba, Dixie-Lee Esseltine, Andrew Cakana, Lixia Pei, Helgi van de Velde, Jesus San Miguel
: Bortezomib-melphalan-prednisone (VMP) is a standard-of-care for previously untreated, transplant-ineligible multiple myeloma (MM). Here, we compared outcomes between VMP regimens in the VISTA trial (9-cycle VMP schedule, including 4 cycles of twice weekly bortezomib) and the PETHEMA/GEM05 trial (less intensive 6-cycle VMP schedule with 1 cycle of twice weekly and 5 cycles of weekly bortezomib, then bortezomib-based maintenance). A total of 113 patient pairs matched by propensity score (estimated using logistic regression and incorporating eight exposure/outcome-related parameters) were included in this retrospective analysis...
October 14, 2016: Annals of Hematology
Maya Koren-Michowitz, Noa Lavi, Martin H Ellis, Alessandro M Vannucchi, Ruben Mesa, Claire N Harrison
Extreme thrombocytosis (ExT) has been associated with an increased bleeding risk in myeloproliferative neoplasm (MPN) patients and is included in the high risk category in treatment guidelines. Treatment of patients with ExT has not been studied in prospective trials. To study physicians' approaches to ExT, we distributed a web based questionnaire with clinical case scenarios to 202 members of MPN working groups. Cases included low thrombotic risk essential thrombocythemia (ET) with either JAK2V617F or CALR mutation, polycythemia vera with ExT either with or without leukocytosis, an ET patient needing urgent orthopedic surgery, and a poorly controlled ET patient with acute cerebral venous sinus thrombosis...
October 13, 2016: Annals of Hematology
Maria Liliana Piredda, Gianfranco Catalano, Claudia Ciardi, Mariadomenica Divona, Laura Cicconi, Paola Panetta, Paola Curzi, Eduardo Garza, Carmen Martínez-Losada, Massimiliano Postorino, Francesco Lo-Coco, Nélida I Noguera
No abstract text is available yet for this article.
October 13, 2016: Annals of Hematology
Agata A Filip, Anna Grenda, Sylwia Popek, Dorota Koczkodaj, Małgorzata Michalak-Wojnowska, Michał Budzyński, Ewa Wąsik-Szczepanek, Szymon Zmorzyński, Agnieszka Karczmarczyk, Krzysztof Giannopoulos
Expression of microRNAs is altered in cancer. Circulating miRNA level assessed in body fluids commonly reflects their expression in tumor cells. In leukemias, however, both leukemic and nonleukemic cells compose circulating miRNA expression profile of peripheral blood. The latter contribution to extracellular miRNA pool may result in specific microenvironmental signaling, which promotes proliferation and survival. In our study, we used qT-PCR to assay peripheral blood serum of 22 chronic lymphocytic leukemia (CLL) patients for the expression of 84 miRNAs associated with activation and differentiation of B and T lymphocytes...
October 12, 2016: Annals of Hematology
Julia Montoro, Cristina Robledo, Lurdes Zamora, David Valcárcel, Fernando Ramos
No abstract text is available yet for this article.
October 12, 2016: Annals of Hematology
Monia Ouederni, Monia Ben Khaled, Fethi Mellouli, Elhem Ben Fraj, Nawel Dhouib, Ismehen Ben Yakoub, Selem Abbes, Nejla Mnif, Mohamed Bejaoui
Thalassemia is a common genetic disorder in Tunisia. Early iron concentration assessment is a crucial and challenging issue. Most of annual deaths due to iron overload occurred in underdeveloped regions of the world. Limited access to liver and heart MRI monitoring might partially explain these poor prognostic results. Standard software programs are not available in Tunisia. This study is the first to evaluate iron overload in heart and liver using the MRI T2* with excel spreadsheet for post processing. Association of this MRI tool results to serum ferritin level, and echocardiography was also investigated...
October 12, 2016: Annals of Hematology
Gerardo Colon-Otero, Scott A Van Wier, Greg J Ahmann, Esteban Braggio, Monica L Albertie, Jennifer A Weis, Sikander Ailawadhi, James R Cerhan, Prakash Vishnu, Matthew S Jorgensen, James M Foran, Colleen S Thomas, Rafael Fonseca
The translocation t(14;18)(q32;q21) (BCL-2/J(H)) is present in over 80 % of all follicular lymphomas and is detectable in peripheral blood lymphocytes (PBL) of healthy individuals. The prevalence of this translocation has not been studied in African Americans (AAs). Given the higher incidence of follicular lymphomas in whites compared to AAs in the United States (USA), we hypothesized that the translocation prevalence in the blood of AAs would be lower. DNA was isolated from PBL from blood samples collected from participants from FL...
October 12, 2016: Annals of Hematology
Klára Piukovics, Gabriella Terhes, Tímea Gurbity-Pálfi, Ágnes Bereczki, Ferenc Rárosi, Judit Deák, Zita Borbényi, Edit Urbán
Because of the widespread use of immunosuppressive drugs, CMV infection is one of the most important causes of morbidity and mortality in patients with haematological malignancies worldwide. The aim of the study was to retrospectively analyse the epidemiology of CMV infection in haematological patients. Between 2008 and 2014, 1238 quantitative CMV DNA detections from plasma specimens were performed. These specimens were collected from 271 patients with haematological malignancy. Patients were grouped on the basis of underlying diseases (lymphoid and myeloid malignancies and other haematological diseases)...
October 11, 2016: Annals of Hematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"